INTEGRA LIFESCIENCES HOLDINGS CORP 8-K

What Happened

• Integra LifeSciences Holdings Corp. (IART) filed an 8-K on May 5, 2026 to publish a press release with financial results for the quarter ended March 31, 2026 (attached as Exhibit 99.1). The release includes the company’s quarterly results and forward-looking guidance for organic revenues and adjusted earnings per diluted share.

Key Details

• Filing date: May 5, 2026; quarter reported: ended March 31, 2026.
• The press release includes reconciliations of GAAP to non-GAAP measures for the quarters (and 12-month periods where noted) ended March 31, 2026 and 2025, including: organic revenue, adjusted EBITDA, adjusted net income, adjusted gross profit, adjusted gross margin, adjusted earnings per diluted share, total debt to net debt, and operating cash flow to free cash flow/adjusted free cash flow conversion.
• The company provided forward-looking guidance for organic revenues and adjusted EPS but did not provide reconciliations to the most directly comparable forward-looking GAAP measures because certain GAAP expense items and foreign exchange impacts are highly variable and cannot be reasonably predicted.
• The report was signed by Lea Knight, Executive Vice President and Chief Financial Officer.

Why It Matters

• Investors get the company’s latest quarterly performance and management’s view on near-term organic revenue and adjusted EPS, plus detailed historical reconciliations between GAAP and the non-GAAP metrics management uses.
• Because forward-looking GAAP reconciliations were not provided, investors should note that the guidance is on an adjusted (non-GAAP) basis and may not reflect the full impact of variable GAAP expenses or currency swings. The historical reconciliations in the release help compare past GAAP results to management’s adjusted metrics.